PTN

Palatin Technologies Inc

Feb 25 • 01:14PM ET

19.98

-3.02 -13.13 %

Healthcare • Biotechnology • USA • AMEX

Index	-	P/E	-	EPS (ttm)	-10.13	Insider Own	9.51%	Shs Outstand	1.76M	Perf Week	3.26%
Market Cap	35.41M	Forward P/E	-	EPS next Y	-2.23	Insider Trans	-0.33%	Shs Float	1.60M	Perf Month	22.43%
Enterprise Value	21.28M	PEG	-	EPS next Q	-1.24	Inst Own	47.56%	Short Float	12.57%	Perf Quarter	-12.45%
Income	-9.63M	P/S	3.95	EPS this Y	86.82%	Inst Trans	-	Short Ratio	4.12	Perf Half Y	87.43%
Sales	8.96M	P/B	3.06	EPS next Y	47.29%	ROA	-86.59%	Short Interest	0.20M	Perf YTD	29.91%
Book/sh	6.53	P/C	2.45	EPS next 5Y	54.06%	ROE	-378.67%	52W High	49.50 -59.64%	Perf Year	-56.59%
Cash/sh	8.17	P/FCF	-	EPS past 3/5Y	44.66% 23.09%	ROIC	-83.03%	52W Low	1.75 1041.71%	Perf 3Y	-85.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-4.89%	Volatility	13.16% 10.62%	Perf 5Y	-98.05%
Dividend TTM	-	EV/Sales	2.37	EPS Y/Y TTM	87.54%	Oper. Margin	-139.45%	ATR (14)	2.17	Perf 10Y	-96.80%
Dividend Ex-Date	-	Quick Ratio	2.76	Sales Y/Y TTM	2461.02%	Profit Margin	-107.41%	RSI (14)	56.00	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.76	EPS Q/Q	51.67%	SMA20	11.29%	Beta	0.39	Target Price	54.33
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	12.10%	Rel Volume	0.70	Prev Close	23.00
Employees	29	LT Debt/Eq	0.01	Earnings	Feb 17 BMO	SMA200	76.06%	Avg Volume	48.76K	Price	19.98
IPO	Oct 28, 1993	Option/Short	No / Yes	EPS/Sales Surpr.	-21.53% 364.00%	Trades		Volume	20,462	Change	-13.13%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-25	Initiated	Laidlaw	Buy	$60
Dec-03-25	Initiated	Alliance Global Partners	Buy	$50

Feb-17-26 06:00PM	Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com) +10.01%
07:30AM	Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-13-25 07:30AM	Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-12-25 12:15PM	Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option (PR Newswire) +29.43%

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILLS STEPHEN T	Executive VP and CFO/COO	Dec 24 '25	Sale	16.74	565	9,461	63,488	Dec 29 04:30 PM
WILLS STEPHEN T	Director	Dec 24 '25	Proposed Sale	16.74	565	9,461		Dec 29 10:42 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTN

Palatin Technologies Inc

Upgrade your FINVIZ experience